Related Experiment Video
Updated: Aug 10, 2026
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
2-5A antisense telomerase RNA therapy for intracranial malignant gliomas
1Center for Surgery Research, The Cleveland Clinic Foundation, Ohio 44195, USA.
Abstract:
Malignant gliomas are the most common intracranial tumors and are considered incurable. Therefore, exploration of novel therapeutic modalities is essential. Telomerase is a ribonucleoprotein enzyme that is detected in the vast majority of malignant gliomas but not in normal brain tissues. We, therefore, hypothesized that telomerase inhibition could be a very promising approach for the targeted therapy of malignant gliomas. Thus, 2-5A (5'-phosphorylated 2'-5'-linked oligoadenylate)-linked antisense against human telomerase RNA component (2-5A-anti-hTER) was investigated for its antitumor effect on an intracranial malignant glioma model. 2-5A is a mediator of one pathway of IFN actions by activating RNase L, resulting in RNA degradation. By linking 2-5A to antisense, RNase L degrades the targeted RNA specifically and effectively. Prior to the experiments using intracranial tumor models in nude mice, we modified the in vitro and in vivo treatment modality of 2-5A-anti-hTER using a cationic liposome to enhance the effect of 2-5A-anti-hTER. Here we demonstrate that 2-5A-anti-hTER complexed with a cationic liposome reduced the viability of five malignant glioma cell lines to 20-43% within 4 days but did not influence the viability of cultured astrocytes lacking telomerase. Furthermore, treatment of intracranial malignant gliomas in nude mice with 2-5A-anti-hTER was therapeutically effective compared with the control (P < 0.01). These findings clearly suggest the therapeutic potentiality of 2-5A-anti-hTER as a novel approach for the treatment of intracranial malignant gliomas.
Insights
This study explored 2-5A-linked antisense against human telomerase RNA component (2-5A-anti-hTER) for malignant glioma treatment. The novel therapy effectively reduced glioma cell viability and tumor growth in mice.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Malignant gliomas are aggressive brain tumors with poor prognoses.
- Telomerase is highly expressed in malignant gliomas, making it a potential therapeutic target.
- Novel therapeutic strategies are crucial for treating these incurable intracranial tumors.
Purpose of the Study:
- To investigate the antitumor efficacy of 2-5A-linked antisense against human telomerase RNA component (2-5A-anti-hTER) in an intracranial malignant glioma model.
- To evaluate the potential of telomerase inhibition as a targeted therapy for malignant gliomas.
- To assess the enhanced therapeutic effect of 2-5A-anti-hTER complexed with cationic liposomes.
Main Methods:
- Development and in vitro testing of 2-5A-anti-hTER complexed with cationic liposomes against malignant glioma cell lines and astrocytes.
- In vivo evaluation of the therapeutic efficacy of 2-5A-anti-hTER in an intracranial malignant glioma mouse model.
- Assessment of cell viability and tumor growth inhibition.
Main Results:
- 2-5A-anti-hTER with cationic liposomes significantly reduced malignant glioma cell viability (20-43%) within 4 days.
- The treatment did not affect the viability of normal astrocytes lacking telomerase.
- Therapeutic administration of 2-5A-anti-hTER demonstrated significant antitumor effects in intracranial malignant glioma models (P < 0.01).
Conclusions:
- 2-5A-anti-hTER, particularly when complexed with cationic liposomes, shows significant therapeutic potential for malignant gliomas.
- Targeting telomerase via 2-5A-anti-hTER offers a promising novel therapeutic approach for intracranial malignant gliomas.
- This targeted therapy warrants further investigation for clinical application in glioma treatment.
